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ABSTRACT
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal malignancies 
of the gastrointestinal tract. Most GISTs harbor a c-KIT (80%) or a PDGFRα (10%) 
mutation that leads to constitutive activation of the tyrosine kinase receptor. Response 
to treatment with tyrosine kinase inhibitors (TKIs) is dependent on mutational status 
of the tumor. The most common mutation in PDGFRα, D842V, is known to be imatinib 
resistant. Almost all other PDGFRα mutations are imatinib sensitive. We describe 
two patients with a PDGFRα exon 18 mutated GIST responding to treatment with 
TKIs. One of these patients has a p.M844_S847 deletion, not previously described 
in relation with TKI treatment response. Mutations in circulating tumor DNA were 
detectable with digital droplet PCR in serial plasma samples taken during treatment 
and correlated with treatment response of both patients. Computer 3D-modeling of 
the PDGFRα kinase domain of these two variants revealed no direct interference in 
imatinib or sunitinib binding and no effect in its activity in contrast to the reported 
structure of the imatinib resistant D842V mutation.
An overview is given of the literature regarding the evidence of patients with 
different PDGFRα mutated GISTs on response to TKIs. The findings emphasize the use 
of mutational analysis in GIST to provide patients personalized treatment. Detection 
of mutations in plasma is feasible and can provide real-time information concerning 
treatment response. We suggest to register GIST patients with these uncommon 
mutations in a prospective international database to understand the tumor biology 
and obtain more evidence of such mutations to predict treatment response.
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are rare 
mesenchymal malignancies of the gastrointestinal tract 
with an incidence of 10 cases per million people [1]. About 
50% of GIST arises in the stomach, 30% in the small 
intestine and 20% in other parts of the gastrointestinal tract 
[2]. Tumors originate from the interstitial cells of Cajal (or 
its precursor cells), the smooth muscle pacemaker cells. 
Constitutively activating mutations in the genes coding 
for the tyrosine kinase receptors KIT or platelet derived 
growth factor alpha (PDGFRα) play a crucial role in the 
biology of these tumors [3]. Approximately 80% of GIST 
harbor mutations in KIT, 10% in PDGFRα. The remaining 
part are wild type, has a BRAF mutation or inactivation of 
the SDH complex. KIT exon 11 mutant tumors can occur 
anywhere in the gastrointestinal tract, whereas PDGFRα-
mutant tumors arise primarily in the stomach, mesentery 
and omentum. KIT exon 9 mutant tumors are mostly 
found in the small intestine [4]. 
                                                          Case Report
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Surgery is the only curative treatment and treatment 
of choice when feasible. Patients with irresectable tumors 
due to local advancement or metastatic disease can be 
treated with imatinib mesylate, a KIT selective tyrosine 
kinase inhibitor (TKI) in neo-adjuvant and palliative 
setting. Response on systemic treatment is strongly 
dependent on mutational status of the tumor. Patients with 
an imatinib-sensitive mutation have a response or stable 
disease for a median time of 27 months [5]. When imatinib 
treatment fails, second line treatment with sunitinib and 
third line treatment with regorafenib is available [6]. 
Resistance in patients who have an imatinib sensitive 
primary mutation occurs often as a result of secondary 
mutations in the tumor that develop during treatment [7]. 
After potentially curative surgery, patients with PDGFRα 
mutations and those with wild-type GIST have a lower risk 
of recurrence than patients with KIT mutations [8]. Once 
recurrences occur, the most common PDGFRα mutation 
in exon 18 (D842V) is known to be resistant to imatinib 
treatment. But not all GISTs with a mutation in exon 18 of 
the PDGFRα gene are resistant to treatment with a TKI. 
Since the introduction of mutation analysis in biopsies of 
GIST tumors, it is known that specific PDGFRα mutations 
appear to be imatinib sensitive [9]. Response to therapy 
is generally evaluated by radiological imaging. Recent 
advances in molecular biology enable the detection of 
tumor mutations in circulating tumor DNA (ctDNA) 
in plasma. This plasma mutational load can reflect the 
treatment response and current disease state [10].
Two patients with various PDGFRα deletions who 
responded on TKI treatment are described and serial 
plasma samples of both patients were analyzed with digital 
droplet PCR (ddPCR). Finally, an overview of literature 
concerning PDGFRα mutations in GIST is presented.
Clinical summary patient 1
A 76-year old man was referred with a large 
abdominal tumor suspected for GIST. His WHO-
performance score at first presentation was 3, being bed 
bound for the majority of the day. CT and FDG-PET 
scan showed a 29 cm large, irresectable tumor without 
evidence of metastases (Figure 1A). Mutation analysis 
on the performed biopsy specimen confirmed the 
diagnosis GIST with a mutation in exon 18 of PDGFRα 
(NM_006206.5: c.2531_2542del; p.(M844-S847del)). 
Treatment with imatinib 400 mg once daily was initiated 
in a neo-adjuvant setting. After one week he reported a 
clinical relevant benefit by disappearance of nausea and 
increasing energy levels. On the CT-scans performed 
every three months, stable disease was seen during one 
year of treatment. Based on a growing nodule (Figure 
1B), progression was suspected and surgical resection 
of the tumor was considered. However, progression with 
peritoneal metastasis was seen on the following CT scan 
three months thereafter. Surgery with curative intent was 
Figure 1: CT images of patient 1. Primary GIST (red area), liver metastases (red circles) and ascites (green) are indicated. A. Pre-
treatment scan. B. After 12 months imatinib treatment, growing nodule. Start sunitinib. C. 6 months on sunitinib, stable disease. D. One 
year sunitinib. Progression. Ascites, liver metastasis. Start regorafenib. E. 3 months regorafenib, stable disease. Demarquation of the liver 
metastasis is seen as response on therapy. F. 6 months regorafenib, progression, more liver metastases are seen.
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no longer feasible and 15 months after start of imatinib, 
treatment was switched to second line treatment with 
sunitinib 37.5mg daily. The patient responded during one 
year on sunitinib (Figure 1C), until he was admitted to 
the hospital with malaise and ascites based on disease 
progression (Figure 1D). He recovered after drainage of 
ascites. A biopsy of a progressive nodule was performed 
and treatment with regorafenib (160mg daily for 3 out of 
4 weeks) was started. With this regimen stable disease 
during 5 months was obtained (Figure 1E). He died one 
month after stopping treatment with regorafenib due to 
progressive disease (Figure 1F), no clinical benefit was 
reached with a re-challenge of imatinib. Plasma samples 
were available during treatment with regorafenib and 
4th line imatinib. An increase in mutational copies/ml is 
seen between stable disease (Figure 1E) and progression 
(Figure 1F) of 180 to 850 mutant copies/ml (Figure 3A). 
At the last visit to the outpatient clinic (two weeks before 
death), mutant copies were 4767 copies/ml (month 33). 
In total, this patient responded or had stable disease 
according to RECIST criteria for 32 months on several 
tyrosine kinase inhibitors. Mutation analysis performed on 
the progressive tumor nodule before start of regorafenib 
showed the same p.(M844_S847del) (c.2531_2542del) 
mutation in exon 18 of PDGFRα as detected in the primary 
tumor, whereas no additional mutations were found in 
exon 12 and 14 of PDGFRΑ nor in exon 9, 11, 13, 14, 
17 of KIT (the average coverage is ~2000 reads in tumor 
DNA with neoplastic content of 80%). Detection of the 
primary mutation in plasma reflected the clinical course 
of the disease in this patient. 
Clinical summary patient 2
A 76-year old woman was referred for analysis of 
abdominal pain. A CT scan showed a large abdominal 
tumor (diameter 25 cm) with multiple liver metastases 
(Figure 2A and 2B). Biopsy of a liver metastasis showed a 
CD117 positive tumor, characteristic for GIST. Mutational 
analysis showed no mutation in KIT, PDGFRα analysis 
was not performed at the time.
Treatment with imatinib 400 mg daily was initiated 
and after ten days she had clinical benefit. She tolerated 
the treatment well and a partial response was seen on the 
CT-scan performed every 3 months (Figure 2C and 2D). 
After 30 months of treatment progression of the primary 
tumor as well as the liver metastases was seen (Figure 2E 
and 2F). Additional mutation analysis was performed on 
the biopsy taken at diagnosis and revealed a PDGFRα 
exon 18 (NM_006206.5: c.2527_2538del; p.(I843_
D846del)) mutation (the average coverage is ~2500 reads 
in tumor DNA with neoplastic content of 95%). Treatment 
was continued with increased dosage of imatinib 400 mg 
twice daily and the patient tolerated this dosage, yet no 
clinical and radiological response was seen (progressive 
lesions on CT-scan after 3 months treatment, Figure 2G 
and 2H). Two months after the treatment was switched to 
sunitinib 37.5mg daily the patient continued to deteriorate 
and she died 36 months after the initial diagnosis. A 
tissue biopsy of a progressive lesion was not available to 
evaluate the secondary mutational status. Blood samples 
for ctDNA analysis (Figure 3B) were first drawn after 
16,5 months of treatment with imatinib 400mg (6 mutant 
copies/ml). The mutant copies level remained stable until 
progressive disease was detected at the CT scan at 30 
months. After initiation of imatinib 400mg twice daily an 
increase in mutant copies (5 to 275 /ml) was detected. The 
mutational level continued to rise to 852 mutant copies/
ml corresponding with progressive disease on the CT 
scan performed at 33 months. After initiation of sunitinib 
treatment, a decrease in mutant copies (208 mutant copies/
ml) was measured. Unfortunately, no further samples were 
available for analysis since the patient deceased after 2 
months. 
Mutational analysis
For mutational analysis, DNA was extracted from 
formalin-fixed, paraffin-embedded (FFPE) tumor tissue 
using the Cobas DNA extraction kit (Roche, Basel, 
Switzerland). Next generation sequencing (NGS) analysis 
using the University Medical Center Groningen onco-
panel on the Ion-Torrent platform (Thermo Fischer 
Scientific, Waltham, MA, USA) was performed. Torrent 
Suite Software was used to pre-process the raw data, and 
base calling, alignment, coverage analysis and variant 
calling was performed using SeqNext software (JSI 
medical systems GmbH) as reported previously [11]. 
According to international guidelines for clinical NGS 
panels [12], the minimal depth of coverage was set at 250 
reads per tested amplicon. This to confidently identify 
also low frequency relevant variants in clinical tissues 
resulting from heterogeneity due to admixture of non-
neoplastic cells, intratumoral variations (different clones) 
and viability of tumor cells. Relevant exons that are tested 
with this panel included KIT exons 8, 9, 11, 13, 14, 17 and 
PDGFRα exons 12, 14, 18 and BRAF codon 594, 599, 600 
(www.moloncopath.nl).
Computer 3D-modeling of the PDGFRα kinase 
domain
Computer 3D-modeling of the activation loop in 
the kinase domain of PDGFRα was recently reported to 
stabilize the kinase in the inactive state and to facilitate 
the binding of imatinib. The crystal structure with the 
D842V mutation suggested activation of the kinase and 
kinetic data confirmed an increased affinity for ATP 
both in agreement with the observed drug resistance in 
patients with the D842V mutation [13]. To evaluate the 
possible consequences of the I843_D846del and M844_
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Figure 2: CT images of patient 2, left column images of pelvis, right column images of liver at the same time. Primary 
tumor (red area), metastases (red circles). A. Pretreatment, large tumor in the lower abdomen. B. Pretreatment, multiple liver metastases. 
C. 24 months imatinib, treatment response. D. 24 months imatinib, demarquation of metastases. E. 30 months imatinib, progressive tumor 
nodule (red circle). F. 30 months imatinib, progression liver metastases. G. 33 months, multiple progressive nodules (red circle). H. 33 
months, progression of liver metastases.
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S847del variants on the activation loop of PDGFRα, three 
3D-models (PDGFRα-D842V, PDGFRα-M844_S847del 
and PDGFRα- I843_D846del) were built (Figure 4). The 
predicted orientation of D842, described to be essential 
for the auto-inhibited state of the tyrosine kinase domain 
[9], was conserved. The proposed hydrogen bond between 
D842 and H845(PDB; 4BKJ [14]) is almost certainly not 
formed, as the geometry of the interaction does not fall 
close to experimentally determined angular distributions 
[15]. Our 3D-modeling indicates that the PDGFRα M844_
S847del and I843_D846del variants would play no role in 
activation. 
In order to evaluate whether these 2 variants affect 
residues of PDGFRα that specifically interact with 
imatinib, the reported structure of the tyrosine kinase 
domain of DDR1 bound to imatinib (PDB; 4BKJ [14]) was 
used as template for homology modeling (35% sequence 
identity) [16]. Our model predicts that imatinib interacts 
with the same amino acids of DDR1 (E672, T701, V763, 
H764, D784) that are conserved in PDGFRα (E644, 
T674, V815, H816, D836). Considering that the PDGFRα 
M844_S847del and I843_D846del variants do not affect 
these 5 residues, it is highly likely that these variants will 
not directly affect binding of imatinib or sunitinib.
Figure 3: Serial plasma samples were analyzed during treatment. The PDGFRα mutant copies/ml level as tested with ddPCR 
are shown. A. Patient 1 with the p.M844-S847del; c.2531_2542del variant. First plasma samples was collected 31 months after start of 
treatment, disease progression as determined with CT after 32 months corresponded with a rise in mutant copies/ml. Patient died 33 months 
after start of first treatment. B. Patient 2 with the p.I843_D846del; c.2527_2538del variant. First plasma sample was collected 16,5 months 
after start of treatment, disease progression at 30 months was not detected in plasma ctDNA, however after switch of therapy an increase in 
mutant copies/ml is detected corresponding with disease progression on CT at 32 months. After initiation of sunitinib, a decrease in mutant 
copies ml is seen. Patient died 36 months after initial diagnosis. 
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Analysis of circulating tumor DNA
Blood samples were collected in EDTA tubes 
(vacutainer #367525, Becton Dickinson, Franklin 
Lakes, NJ, USA) and processed within 4 hours after 
vena puncture. Samples were processed and isolation 
of DNA were performed as described elsewhere 
[17]. Digital droplet PCR (ddPCR) primers and 
probes was in-house designed and ordered at IDT 
(Coralville, IA, USA). The primer sequences for patient 
1 (p.M844_S847del; c.2531_2542del) were Fwd. 
5’-CTCCTGGCACAAGGAAA-3’ (c.2473-c.2489) 
and Rev. 5’-GGACGTACACTGCCTTT-3’ 
(c.2554-c.2570) resulting in a PCR product of 98 
base pairs. The sequence of probe I (FAM) was 
5’-GCCAGAGACATCAACTATGTGTCG-3’ and probe 
II (HEX) 5’-CATGCATGATTCGAACTATGTGTCG-3’. 
For patient 2 (p.I843_D846del; c.2527_2538del) 
the primer sequences were Fwd. 
5’-ATTGTGAAGATCTGTGACTTTG-3’ 
(position c.2491-c.2512) and Rev. 
5’-AGTGAGGGAAGTGAGGA-3’ (position 
c.2568-c.2584) resulting in a PCR product of 94 
base pairs. The sequence of probe I (FAM) was 
5’-GCCAGAGACTCGAACTATGTGTCG-3’ and probe 
II (HEX) 5’-TGCATGATTCGAACTATGTGTCGAA-3’. 
Temperature gradient PCR of the primers and probes were 
performed to detect the optimal annealing temperature and 
resulted in an optimal PCR temperature of 55˚C for both 
assays. The specific assays were validated on available 
tumor tissue. DdPCR was performed on a T100 Thermal 
Cycler (Bio-Rad, Hercules, CA, USA) and samples were 
transported to the QX200 Droplet Reader (Bio-Rad) for 
fluorescent measurement of FAM and HEX probes, data 
was analyzed with Quantasoft software version 1.6.6.
REVIEW OF THE LITERATURE
PDGFRα mutations and response on imatinib
PubMed was searched for articles concerning 
GIST patients with PDGFRα mutations and response to 
treatment with imatinib. Data of 14 papers and a total of 
Figure 4: Residue 842 of human PDGFRα. A. Residue D842 (in red) in the structure of wild type PDGFRα (pdb 5K5X). B. Residue 
D842 in the structure of wild type PDGFRα modeled with variant M844_S847del. C. Residue D842 in the structure of wild type PDGFRα 
modeled with the I843_D846del variant. D. Residue V842 (in grey) in the structure of wild type PDGFRα modeled with mutation D842V. 
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102 patients with PDGFRα exon 18 mutated GIST were 
retrieved by our search strategy (Figure 5). 
Five of the fourteen papers describe data of 
progression free survival (PFS) or overall survival (OS) of 
patients with a PDGFRα mutated advanced GIST treated 
with imatinib (Table 1). A 10-fold increase in PFS is seen 
in patients with non-D842V mutated GIST compared with 
D842V mutated who were treated with imatinib. Recently, 
a series of 823 GIST patients including 13 patients with a 
PDGFRα exon 18 mutated GIST who were treated with 
first line imatinib is described [18]. The OS of patients 
with a D842V mutation was 25.2 months compared to 
59.8 months for patients with a non-D842V PDGFRα 
mutated GIST (p=0.02). At least two other studies 
showed a better median OS in patients with a non-D842V 
PDGFRα mutation compared to patients with a D842V 
mutation [18, 19]. 
In COSMIC (catalogue of somatic mutations in 
cancer; www.cancer.sanger.ac.uk/cosmic) the p.M844_
S847del mutation is described in eight patients in five 
studies. All patients were treated surgically and had 
no evidence of disease or recurrence afterwards, so no 
information was reported regarding the response on 
treatment (Table 2). 
A few patients with a GIST with a p.I843_D846del 
mutation have been described, although information 
regarding the response to TKI treatment is scarce [20, 37-
47].
Response on sunitinib as second line treatment
Two papers report on response to second-line 
treatment with sunitinib. In nine patients, no objective 
response was seen [18]. Patients with the D842V 
mutation tended to show poorer PFS than those with non-
D842V PDGFRα mutations (median PFS 1.9 months for 
D842V mutant vs. 7.3 months for non-D842V PDGFRα 
mutations; P = 0.26). Another cohort consisted of 11 
patients with a PDGFRα mutated GIST [20]. Of those 
patients, three had disease stabilization for more than 6 
months. No significant difference could be shown between 
the different PDGFRα mutations (PFS 2.1 months for 
D842V mutant and 7.8 months for other mutations, P = 
0.2489).
Figure 5: Flow-chart of search strategy. In total 61 articles were excluded because of other study questions or insufficient data, 
resulting in 14 papers eligible for analysis.
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DISCUSSION
Our two case patients with a non-D842V PDGFRα 
mutation responded or had prolonged periods of non-
progressive disease to various tyrosine kinase inhibitors. 
Although patients with advanced disease and a PDGFRα 
mutation can respond to treatment with imatinib, the 
overall survival of these patients is worse than that of 
patients with a KIT mutation bearing GIST. This is 
reported in studies with advanced GIST patients where 
a median survival of 57 months for patients expressing 
KIT compared to a median overall survival of 23.7 months 
for patients with a PDGFRα mutation is reached [20, 48]. 
Imatinib resistance was reported most frequently in GIST 
patients with PDGFRα mutations and wild type GISTs. 
However, the PDGFRα mutations were not specified 
[49]. In contrast to the mutation distribution described 
in literature of 10% PDGFRα mutations in GIST, most 
articles report a much lower fraction of patients with 
PDGFRα mutations, suggesting underreporting. 
To our knowledge, this is the first report regarding 
a p.M844_S847del variant in relation to TKI treatment. 
We show the clinical importance of mutation detection as 
patients with specific PDGFRα mutations respond well 
on imatinib treatment. The published reports that were 
found in the PubMed search provide limited PFS and 
OS data. However, patients with a non-D842V mutation 
have a favorable prognosis when treated with imatinib 
compared to patients with a D842V PDGFRα mutated 
GIST. A recent report showed a better overall survival 
in patients with non-D842V when treated with imatinib 
compared to patients with D842V mutated tumors [18]. 
Due to the latter it is of great importance to differentiate 
between those. 
The frequency of recurrence after surgery is lower 
in patients with gastric versus non-gastric PDGFRα 
mutated GIST, similar to patients with other mutations 
[50]. In metastatic D842V mutated GIST the role of TKI 
Table 2: Overview of the literature regarding p.M844_S847 PDGFRα deletion
* Follow up time is not reported
Table 1: Patient numbers and survival data of 14 papers found by the performed literature search.
NR = not reached, PD = progressive disease, SD = stable disease, m = month, fu = follow up
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is very limited and the prognosis is clearly far inferior to 
other mutated GISTs [51, 52]. Several new therapies are 
being investigated for patients with a PDGFRα (D842V) 
mutation [27, 53], however none of them are already 
available for daily clinical practice. 
TKI sensitive mutations are mostly located near 
the imatinib resistant D842V domain. It has been implied 
that primary resistance to imatinib correlates specifically 
with substitution mutations that affect residue D842 of the 
kinase activation loop [9]. Modifications of this domain 
are interfering with a swinging movement of the activation 
loop. This movement is linked to a conformational shift 
of the ATP binding pocket from an “open” or active set-
up to a “closed” or inactive set-up. Since imatinib is an 
ATP competitor and binds exclusively to the closed form 
of the kinase, substitutions of PDGFRα D842 reduce the 
accessibility of the ATP pocket and thereby give relative 
resistance to the drug [13]. An increased affinity for ATP of 
the mutated tyrosine kinase domain has also been reported 
to contribute to the acquired resistance to imatinib [54]. 
In contrast to D842V, our 3D-modeling of the kinase 
activation loop indicates that the M844_S847del and 
I843_D846del variants would play no role in activation. 
In addition, homology modeling predicted that imatinib 
interacts with 5 residues in PDGFRα (E644, T674, V815, 
H816, D836) conserved with those in DDR1. Because the 
PDGFRα M844_S847del and I843_D846del variants do 
not affect these 5 residues, it is highly likely that these 
variants will not directly affect binding of imatinib or 
sunitinib. In summary, our 3D-modeling analysis indicates 
that PDGFRα proteins harboring the M844_S847del and 
I843_D846del variants would not directly interfere in 
imatinib or sunitinib binding and would not affect activity. 
Consequently, both variants would still allow binding 
and inhibition of imatinib and sunitinib. This is in good 
agreement with the observed response to imatinib in these 
two patients. However, to assess sensitivity to tyrosine 
kinase inhibitors of these particular mutations, cell line-
based drug sensitivity analysis would be of added value.
Secondary resistance usually occurs between 6-24 
months after start of imatinib treatment. Secondary 
mutations as cause of TKI insensitivity have been found 
in patients with primary KIT mutations and rarely in 
patients with primary PDGFRα mutations [5]. Alternative 
pathways for secondary resistance are activation of 
other growth pathways and loss of the remaining wild-
type PDGFRα and overexpression of PDGFRα or other 
tyrosine kinase receptors [55]. In patient 1, a biopsy at 
progression was taken. However, in addition to the M844_
S847del variant in exon 18 of PDGFRα, no secondary 
treatment resistant mutations were detected with NGS.
The detection of mutations in circulating tumor 
DNA from cell free plasma (ctDNA) of patients with 
GIST has been reported before [56-60]. In this study we 
report on the correlation between clinical course/treatment 
response and the detection of the tumor-specific PDGFRA 
mutations in ctDNA of serially taken blood samples of 
these 2 patients with GIST, showing the use of mutation 
detection in ctDNA in plasma to monitor treatment 
response. In patient 1, the clinical course correlated well 
with the ctDNA level. However, in patient 2 the moment 
of progression on first line treatment was not detected 
in the ctDNA. According to the CT scan at 30 months 
(Figure 2E/F) there is one progressive nodule detected 
implying treatment resistance. Some lesions became 
larger, but have a cystic aspect what in GIST could match 
with treatment response. Since there is little active tumor 
tissue, we suggest the limited DNA shed of the progressive 
nodule in this phase is below the detection level of ddPCR. 
The following CT scan (Figure 2G/H) shows massive 
progression which is preceded by a detectable rise in 
mutant ctDNA copies. Further research has to reveal the 
clinical value of detectable mutant ctDNA copies.
In conclusion, the p.M844_S847del and p.I843_
D846del mutations are rare but have clinical importance 
since these specific mutations are associated by a 
response to treatment with TKIs. This report emphasizes 
the importance of mutational analysis of tumors and 
is exemplary for the implementation of personalized 
medicine. Mutational analysis should be performed 
of each primary and resistant tumor to increase the 
knowledge of primary and secondary resistant mutations. 
Mutation detection in ctDNA to assess treatment response 
seems feasible. We suggest to register patients with 
very uncommon genetic aberrations in a prospective 
international database to understand the tumor biology 
and obtain more evidence to predict treatment response 
and eventually contributing to the development of new 
targeted therapies. 
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